Abeona Therapeutics Announces Upcoming Conference Participation
22 sept. 2017 08h45 HE
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Sept. 22, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene...
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa
29 août 2017 09h05 HE
|
Abeona Therapeutics Inc
FDA recently guided Company to accelerate Phase 3 trial for EB-101 autologous cell therapyBreakthrough Therapy designation enables priority review and expedites approval processEB-101 has demonstrated...
Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017
17 août 2017 09h15 HE
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Aug. 17, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A
16 août 2017 09h25 HE
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies...
Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa
18 juil. 2017 08h05 HE
|
Abeona Therapeutics Inc
Pivotal Phase 3 clinical trial is planned to commence in early 2018 EB-101 gene therapy for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) has demonstrated promising efficacy and...
Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program
29 juin 2017 08h15 HE
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, June 29, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Receives Rare Pediatric Disease Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis Bullosa
30 mai 2017 08h05 HE
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 30, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics to Present at Multiple Upcoming Conferences
19 mai 2017 08h05 HE
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 19, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Highlights
16 mai 2017 08h05 HE
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...
Abeona Therapeutics Announces Gene Therapy Clinical Trial and Preclinical Program Presentations at ASGCT 20th Annual Meeting
08 mai 2017 08h05 HE
|
Abeona Therapeutics Inc
NEW YORK and CLEVELAND, May 08, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for...